Journal of Modern Oncology最新文献

筛选
英文 中文
Do cancer vaccines help people with advanced non-small cell lung cancer? (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review) 癌症疫苗对晚期非小细胞肺癌患者有帮助吗? 科克伦系统综述的通俗语言摘要 (PLS) 俄译文
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202806
{"title":"Do cancer vaccines help people with advanced non-small cell lung cancer? (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)","authors":"","doi":"10.26442/18151434.2024.2.202806","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202806","url":null,"abstract":"This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Cortés-Jofré M, Rueda-Etxebarria M, Orillard E, Jimenez Tejero E, Rueda J-R. Therapeutic vaccines for advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews 2024, Issue 3. Art. No.: CD013377. DOI: 10.1002/14651858.CD013377.pub2","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"2 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141681284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term dynamics of epidemiological characteristics of some chronic leukemia and lymphoma in Moscow before, during and after the pandemic of the new coronavirus infection COVID-19. Epidemiologic study 新型冠状病毒感染 COVID-19 流行之前、期间和之后莫斯科一些慢性白血病和淋巴瘤流行病学特征的长期动态变化。流行病学研究
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202776
O. Vinogradova, Mikhail V. Chernikov, A. L. Neverova, Victoria P. Kosenkova, Yulia B. Kochkareva, D. I. Shikhbabaeva, M. Pankrashkina, Nikolai N. Sharkunov, V. Ptushkin
{"title":"Long-term dynamics of epidemiological characteristics of some chronic leukemia and lymphoma in Moscow before, during and after the pandemic of the new coronavirus infection COVID-19. Epidemiologic study","authors":"O. Vinogradova, Mikhail V. Chernikov, A. L. Neverova, Victoria P. Kosenkova, Yulia B. Kochkareva, D. I. Shikhbabaeva, M. Pankrashkina, Nikolai N. Sharkunov, V. Ptushkin","doi":"10.26442/18151434.2024.2.202776","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202776","url":null,"abstract":"Background. The COVID-19 pandemic, which swept the world in 2020–2021, had a significant impact on the epidemiological picture of hematological malignancies. \u0000Aim. To study the dynamics of epidemiological indicators of five chronic hemoblastoses in Moscow over a 12-year period, and also to assess the impact of the COVID-19 pandemic on these indicators. \u0000Materials and methods. A population-based study was conducted for five types of oncohematological diseases: multiple myeloma, Hodgkin's lymphoma, follicular lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia. The annual rates of morbidity, mortality, prevalence of these nosologies, overall survival, and expected overall survival were calculated. Gender and age characteristics for each disease were determined. \u0000Results and discussion. The present study showed a uniform increase in the incidence and prevalence of five hematological malignancies between 2012 and 2019. Convincing evidence of an increase in mortality and a decrease in the number of diagnosed cases in comparison with the expected figures for these hematological malignancies in 2020–2021 was presented. A greater reduction was shown for cases diagnosed at early stages compared to later ones. During the pandemic, a significant increase in mortality was recorded among patients with chronic lymphocytic leukemia and multiple myeloma, while in cohorts of patients with chronic myeloid leukemia and Hodgkin lymphoma it increased slightly. The return of morbidity, mortality and prevalence rates to the original dynamics in 2022–2023 has been demonstrated. \u0000Conclusion. This study demonstrated the features of the regional pattern of incidence, mortality, prevalence and gender-age characteristics of five hematological malignancies and provided the changes in the indicators dynamics of different hematological malignancies during the COVID-19 pandemic.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"69 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141682374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diffuse large B-cell lymphoma and follicular lymphoma: problem state in Russia 弥漫大 B 细胞淋巴瘤和滤泡淋巴瘤:俄罗斯的问题状况
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202798
I. Poddubnaya, L. Babicheva
{"title":"Diffuse large B-cell lymphoma and follicular lymphoma: problem state in Russia","authors":"I. Poddubnaya, L. Babicheva","doi":"10.26442/18151434.2024.2.202798","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202798","url":null,"abstract":"Background. Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of hematological malignancies, the vast majority of which are B-cell tumors. The most common variant of NHL is diffuse large B-cell lymphoma (DLBCL), characterized by an aggressive course, which accounts for 30–40% of all NHL. The second most common is follicular lymphoma (FL), traditionally classified as an indolent variant accounting for up to 25% of all NHL. Current therapies for these lymphoproliferative disorders which includes innovative drugs in the 1st line of therapy (LT) have demonstrated high efficacy. However, some patients develop a relapse or a refractory disease. Despite recent significant progress in the development and implementation of innovative targeted drugs, in most cases, it is not possible to achieve persistent long-term remissions after disease relapse, which leaves patients with an unmet need for effective and well-tolerated treatment options. \u0000Aim. To obtain objective data on the incidence, clinical course, and effectiveness of therapy for the most common variants of NHL in real-world practice in Russia. \u0000Materials and methods. From February to March 2023, 130 hematologists and oncologists from 30 regions of Russia were surveyed to update the data on DLBCL and FL. \u0000Results. Over the past 12 months, 5,689 patients with NHL were observed, of which 56% had DLBCL; 62% of them received the 1st LT, 22% received the 2nd LT, 10% received the 3rd LT, and only a few reached later lines. Analysis of the administered treatment options in the 2nd and 3rd LTs shows that there is no standard of care for this population, and the effectiveness of the regimens used in real-world Russian practice is extremely low. FL accounted for 23% of all 5,689 patients with NHL, of which 56% were newly diagnosed and 44% received treatment for relapse. The majority of patients with FL who received ≥3 LTs had an inferior prognosis and rapid disease progression: the median time from diagnosis to the beginning of the 3rd LT was only 26.4 months. The analysis of treatment options for patients with relapsed FL indicates a lack of standard and effective therapies. \u0000Conclusion. Relapsed and refractory DLBCL and FL represent a complex clinical situation where the main goal of treatment is disease control due to the impossibility of achieving stable remissions with existing treatment options. Clinicians with great hope are looking to the emergence of new classes of drugs that will be able to improve the prognosis for this complex population.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":" 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141680893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical benefits of parenteral iron carboxymaltose in patients with colorectal cancer: a retrospective observational study 肠外羧甲基铁对结直肠癌患者的临床益处:一项回顾性观察研究
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202751
M. Postolov, V. A. Suvorov, Alina V. Kravets
{"title":"Clinical benefits of parenteral iron carboxymaltose in patients with colorectal cancer: a retrospective observational study","authors":"M. Postolov, V. A. Suvorov, Alina V. Kravets","doi":"10.26442/18151434.2024.2.202751","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202751","url":null,"abstract":"Background. The high incidence of anemia in colorectal cancer and its severe consequences for patients determine the need for timely diagnosis and correction of this condition. At the same time, it is extremely important to choose a method for correcting anemia, allowing to achieve maximum efficiency and safety. \u0000Aim. To evaluate perioperative methods for correcting iron deficiency anemia in patients with colorectal cancer based on a comparative analysis of the clinical results of intravenous administration of iron carboxymaltose and transfusion of blood components. \u0000Materials and methods. The results of treatment of 594 patients with colorectal cancer operated on in 2022 at the department of surgical treatment methods No. 3 (abdominal oncology No. 1) of the Volgograd Regional Clinical Oncology Dispensary were studied. Stratification of patients into groups was carried out using the method of pseudo-randomization by sex and age to eliminate confounding errors. After pseudo-randomization in a 1:1 ratio, the sample of patients with anemia was divided into 2 groups (main group – 124 patients, in whose treatment blood-saving techniques and parenteral administration of iron carboxymaltose were used, and control group – 124 patients, for treatment of anemia in which transfusions of blood components were used). In 98 (39.5%) cases hemicolectomies were performed, in 88 (35.5%) – anterior resections of the rectum, in 36 (14.5%) – resections of the sigmoid colon, in 18 (7.3%) – extirpations of the rectum, in 8 (3.2%) – resection of the transverse colon, 217 (87.5%) operations were performed through laparotomy access, 31 (12.5%) using minimally invasive technologies. \u0000Results. The frequency of postoperative complications of grade III–V according to Clavien–Dindo score in the main group (4.8%, 6/124) was statistically significantly lower compared to the control group (14.5%, 18/124) [χ2=6.643; p=0.01]. Postoperative mortality in the main group was 0.8% (1/124), in the control group – 5.6% (7/124) [χ2=4.65; p=0.032]. \u0000Conclusion. The use of blood-saving technologies with parenteral administration of iron carboxymaltose in patients with colorectal cancer leads to a reduction in the number of postoperative complications and the level of postoperative mortality.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"20 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141681472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is maintenance therapy following previous treatment better than observation or placebo for treating chronic lymphocytic leukaemia in adults? (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review) 在治疗成人慢性淋巴细胞白血病方面,既往治疗后的维持治疗是否优于观察或安慰剂?(科克伦系统综述的通俗语言摘要(PLS)俄文译本)
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202805
{"title":"Is maintenance therapy following previous treatment better than observation or placebo for treating chronic lymphocytic leukaemia in adults? (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)","authors":"","doi":"10.26442/18151434.2024.2.202805","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202805","url":null,"abstract":"This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Lee C-H, Wu Y-Y, Huang T-C, Lin C, Zou Y-F, Cheng J-C, Chen P-H, Jhou H-J, Ho C-L. Maintenance therapy for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2024, Issue 1. Art. No.: CD013474. DOI: 10.1002/14651858.CD013474.pub2","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"230 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141681462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunohistochemical factors of prognosis of immunotherapy for metastatic melanoma: А prospective and retrospective study 转移性黑色素瘤免疫治疗预后的免疫组化因素:前瞻性和回顾性研究
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202803
Liana V. Oganesyan, L. Zavalishina, N. A. Ognerubov, Iuliia V. Kostalanova, Andrey E. Orlov, I. Poddubnaya
{"title":"Immunohistochemical factors of prognosis of immunotherapy for metastatic melanoma: А prospective and retrospective study","authors":"Liana V. Oganesyan, L. Zavalishina, N. A. Ognerubov, Iuliia V. Kostalanova, Andrey E. Orlov, I. Poddubnaya","doi":"10.26442/18151434.2024.2.202803","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202803","url":null,"abstract":"Introduction. Anti-PD-1 immunotherapy (IT) is becoming the standard treatment for patients with metastatic melanoma. However, immune checkpoint inhibitors are only effective in a fraction of patients, and studies examining biological markers and their correlation with clinical efficacy are insufficient to draw unambiguous conclusions. \u0000Aim. To improve the outcomes of the first-line therapy for disseminated melanoma based on identifying clinical and immunohistochemical predictors of IT efficacy. \u0000Materials and methods. Data from 130 patients who were treated with immune checkpoint inhibitors (nivolumab or prolgolimab) in the first-line therapy for disseminated melanoma between 2017 and 2024 were analyzed. \u0000Results. Improvement was observed in 24 patients (18.4%): complete response in 18 patients (13.8%), partial response in 6 (4.6%), and stabilization in 71 (54.6%) patients. Progression was reported in 31 (24%) patients. Death occurred in 4 (3%) cases during IT with prolgolimab due to disease progression. The two-year disease-free survival (DFS) during IT was 53% (95% confidence interval [CI] 42–67), p=0.63; the median 2-year overall survival was not reached. In the immunohistochemical study, 47 (63.5%) patients had a predominance of tumor infiltration with CD8 lymphocytes over CD4, regardless of the IT type: 2-year DFS 82% (95% CI 70–96) vs 13% (95% CI 2.7–64) in the absence of CD8 predominance over CD4, p=0.0001; the median DFS was not reached in patients with the predominance of CD8 lymphocytes tumor infiltration over CD4 compared to the other group – 7.6 months in the absence of this feature (95% CI 5.8–0), p=0.001. The peritumoral location of the immune lymphoid infiltrate was observed in all 74 (100%) patients, and the intratumoral location was less common (52 patients, 70%). In the presence of both periand intratumoral location of the immune infiltrate, the 2-year DFS was 83% (95% CI 70–98) compared to the group of patients in whom no intratumoral location was detected – 5.5% (95% CI 0.8–36), p0.0001. The expression of programmed cell death ligand 1 (PD-L1) level 10% was observed in 47 (63.5%) patients. With this level of PD-L1 expression, the one-year DFS was 91% (95% CI 83–100) compared to 29% (95% CI 15–57) with a lower level of PD-L1 expression, p0.0001; the median DFS is reached, and in the group 2, DFS was only 6.6 months. In the case of PD-L110%, the 2-year DFS was high at 78% (95% CI 63–100), p0.0001. \u0000Conclusion. Based on the study's results, it can be assumed that immunohistochemical characteristics such as a PD-L1 expression level 10%, the simultaneous presence of periand intratumoral lymphoid tumor infiltration, and the predominance of CD8 over CD4 can be considered predictors of IT efficacy with nivolumab and prolgolimab.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141680836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of Pembroria® during non-medical switching from Keytruda® in patients with advanced malignant neoplasms of various localizations: the REFLECTION real-world study 在不同部位的晚期恶性肿瘤患者从 Keytruda® 非医疗转换期间使用 Pembroria® 的安全性:REFLECTION 真实世界研究
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202744
E. Choynzonov, A. A. Fedenko, N. Falaleeva, Tatiana V. Andreeva, Sergei G. Afanas'ev, Zelimkhan A. Bakaev, Danila I. Valiev, Aleksandr A. Volkov, L. A. Kolomiets, Tatiana V. Krashikhina, Sergei V. Miller, Viktoriia V. Mikhaliuk, Andrei N. Ogloblin, Svetlana A. Orlova, Stanislav V. Pataliak, I. Pokataev, Nataliia O. Popova, Olesia V. Rebrina, Rustem N. Safin, Irina Iu. Stradaeva, Iuliia V. Trefilova, Inessa S. Usol'tseva, Evgenii A. Usynin, Sergey V. Sharov, Denis Iu. Iukal'chuk, Aishat R. Iasieva
{"title":"Safety of Pembroria® during non-medical switching from Keytruda® in patients with advanced malignant neoplasms of various localizations: the REFLECTION real-world study","authors":"E. Choynzonov, A. A. Fedenko, N. Falaleeva, Tatiana V. Andreeva, Sergei G. Afanas'ev, Zelimkhan A. Bakaev, Danila I. Valiev, Aleksandr A. Volkov, L. A. Kolomiets, Tatiana V. Krashikhina, Sergei V. Miller, Viktoriia V. Mikhaliuk, Andrei N. Ogloblin, Svetlana A. Orlova, Stanislav V. Pataliak, I. Pokataev, Nataliia O. Popova, Olesia V. Rebrina, Rustem N. Safin, Irina Iu. Stradaeva, Iuliia V. Trefilova, Inessa S. Usol'tseva, Evgenii A. Usynin, Sergey V. Sharov, Denis Iu. Iukal'chuk, Aishat R. Iasieva","doi":"10.26442/18151434.2024.2.202744","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202744","url":null,"abstract":"Background. Post-registration observational studies with switching therapy from the original drug to a biosimilar for non-medical indications allow us to assess the safety and effectiveness of this type of switching in real clinical practice. \u0000Aim. Evaluation of the safety and effectiveness of non-medical switching from the original drug Keytruda® to the biosimilar drug Pembroria® in patients with various oncological pathologies in real clinical practice (REFLECTION). \u0000Materials and methods. A retrospective analysis of data from electronic medical records from 21 medical institutions of the Russian Federation for the period 2020–2023 was carried out. Data were included from patients with cancer of various locations who received at least 2 injections of Keytruda® followed by switching to Pembroria® for non-medical indications (at least 2 injections). Primary criteria: incidence of immune-mediated adverse reactions (ImARs) of any severity. Secondary indicators: incidence of ImARs of various degrees of severity and infusion reactions, frequency of objective response rate (according to RECIST 1.1 criteria). \u0000Results. The analysis included data from 382 patients (male/female 200/182, median age 62 years) with NSCLC (24.1%), RCC (23.3%), melanoma (20.4%) and cancer of other localization. Patients received Keytruda® on 1st and 2nd lines (54.2 and 25.4% of patients, respectively), on 3 or 4 lines (14.1%), or as part of adjuvant therapy (6.3%). 50.5% of patients received pembrolizumab as monotherapy. The median number of administrations was 7.0 and 5.0 for Keytruda® and Pembroria®, respectively. ImARs were registered in 44 (11.5%) patients (60 ImARs), including 40 ImARs in 35 (9.2%) patients while using Keytruda® and 20 ImARs in 17 (2.4%) patients with Pembroria®. The most common ImARs were hypothyroidism, hyperthyroidism, and hepatitis; the frequency of these ImARs was higher with Keytruda® (EAER for hypothyroidism 0.00422 and 0.00144, for hepatitis – 0.00124 and 0.00096, respectively). All 5 reported cases of hyperthyroidism in patients on Keytruda® (EAER 0.00124), were resolved before switching to Pembroria®. No infusion-related reactions or deaths due to ImARs have been reported. The objective response rate was comparable – 104 (32.6%) and 90 (29.2%) patients оn Keytruda® and Pembroria® therapy, respectively. Most patients maintained disease control after switching to Pembroria® [progression was recorded in 29 (9.4%) patients after switching to a biosimilar]. \u0000Conclusion. The safety profiles of Keytruda® and Pembroria® were satisfactory and comparable in this study. Switching from therapy with Keytruda® to Pembroria® is not accompanied by an increase in the frequency or severity of ImARs. Switching from Keytruda® to Pembroria® maintains disease control in most patients.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":" 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141681040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second line chemotherapy for advanced biliary cancer: FOLFOX versus FOLFIRI: Analysis of retrospective and prospective data 晚期胆道癌的二线化疗:FOLFOX 与 FOLFIRI:回顾性和前瞻性数据分析
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202753
I. V. Savchenko, I. Stilidi, I. Dzhanyan, E. Antonova, A. N. Polyakov, A. Egorova, S. Chulkova, V. Breder
{"title":"Second line chemotherapy for advanced biliary cancer: FOLFOX versus FOLFIRI: Analysis of retrospective and prospective data","authors":"I. V. Savchenko, I. Stilidi, I. Dzhanyan, E. Antonova, A. N. Polyakov, A. Egorova, S. Chulkova, V. Breder","doi":"10.26442/18151434.2024.2.202753","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202753","url":null,"abstract":"Aim. To evaluate the efficacy and toxicity of second-line polychemotherapy according to FOLFOX or FOLFIRI regimen in patients with biliary tract tumours after progression during first-line chemotherapy (CT). \u0000Materials and methods. The study is based on the analysis of retrospective and prospective data on the examination and treatment of 94 patients with biliary cancer of grades T1-4N0-2M0-1 followed-up and treated at the N.N. Blokhin National Medical Research Center of Oncology from 2015 to 2023. All patients were divided into 2 groups: Group 1 (FOLFOX, n=47) and Group 2 (FOLFIRI, n=47). In Group 1, patients received the recommended FOLFOX second-line CT regimen. Patients in Group 2 received FOLFIRI regimen. The endpoints were overall survival (OS) and incidence of grade 3-4 adverse events. \u0000Results. The study included 94 patients. In the FOLFOX group, the median OS was 13.0 months (1-year OS was 57.8±7.4%); for the FOLFIRI group, the median OS was 12.3 months (1-year OS was 54.4±7.3%). The toxicity profiles of FOLFOX and FOLFIRI were acceptable and consistent with those reported for the regimens. According to the grade 3–4 toxicity data, diarrhea was significantly more common in the FOLFIRI group (p=0.014), and neurotoxicity was more common in the FOLFOX group (p=0.006). During the second-line CT, the frequency of grade 1–4 toxicities in the groups did not differ: 18 (38.3%) events in the FOLFOX group and 19 (40.0%) events in the FOLFIRI group. \u0000Conclusion. Our results of evaluating the efficacy and toxicity of the second-line polychemotherapy regimens show that the FOLFOX and FOLFIRI CT regimens have equal efficacy in patients with advanced biliary tract cancer with a good performance according to the ECOG scale, who previously received the first-line therapy with a combination of gemcitabine with a platinum agent (cisplatin or oxaliplatin); also, our data demonstrate similar toxicity profiles of these regimens.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"164 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141681675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metronomic chemotherapy in pediatric neurooncology: insight the problem. A review 小儿神经肿瘤学中的剂量化疗:洞察问题所在。综述
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202637
Y. Dinikina, O. Zheludkova, M. V. Ryzhova, Liudmila V. Olhova, D. Y. Korneev, M. Belogurova
{"title":"Metronomic chemotherapy in pediatric neurooncology: insight the problem. A review","authors":"Y. Dinikina, O. Zheludkova, M. V. Ryzhova, Liudmila V. Olhova, D. Y. Korneev, M. Belogurova","doi":"10.26442/18151434.2024.2.202637","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202637","url":null,"abstract":"Metronomic chemotherapy (MCT) is a promising direction of anticancer therapy, as well as in pediatric oncology, and its administration in patients with refractory and recurrent tumors of the central nervous system becomes increasingly relevant. Being a regimen of low doses of antitumor agents with different mechanisms of action in a continuous mode for a long time, it allows to overcome the resistance of tumor cells and to minimize the toxic effects of treatment. Today, the issues of rational choice of MCT regimens, which are dependent on the type of tumor, and the application of biomarkers of its effectiveness, remain controversial. The article discusses in detail the biological effects of MCT with an accent on antiangiogenic one, as well as the possibilities and limitations of MCT application in pediatric practice and the results of studies in tumors of the central nervous system.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"40 S187","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141683198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular toxicity of chemotherapy and thyroid status of patients with gastric and colon cancer: Current state of the problem. A review 化疗的心血管毒性与胃癌和结肠癌患者的甲状腺状况:问题的现状。综述
Journal of Modern Oncology Pub Date : 2024-07-03 DOI: 10.26442/18151434.2024.2.202676
I. V. Stanoevich, V. A. Ioutsi, N. L. Lysovolenko, I. E. Alekseev, A. D. Kondrashkina, Maksim B. Polianskii, Ekaterina V. Pis'mennaia
{"title":"Cardiovascular toxicity of chemotherapy and thyroid status of patients with gastric and colon cancer: Current state of the problem. A review","authors":"I. V. Stanoevich, V. A. Ioutsi, N. L. Lysovolenko, I. E. Alekseev, A. D. Kondrashkina, Maksim B. Polianskii, Ekaterina V. Pis'mennaia","doi":"10.26442/18151434.2024.2.202676","DOIUrl":"https://doi.org/10.26442/18151434.2024.2.202676","url":null,"abstract":"Cardiovascular and oncological diseases are the main causes of disability and mortality in Russia, sharing common risk factors and exacerbating each other. The specific toxicological effects of fluoropyrimidines, platinum drugs, and taxanes commonly used in the treatment of gastric and colorectal malignancies have been noted to potentially contribute to the onset of cardiovascular pathologies in some cases. However, the manifestation and prevalence of cardiovascular toxicity due to cancer treatment regimens are influenced by various factors beyond just the chemotherapy protocols employed. Gender, age, overall health status (including cardiac and thyroid functions), and other risk factors play significant roles in the development and progression of heart and vascular diseases in these patients. Thyroid dysfunction, even in the absence of severe clinical symptoms, can significantly impact the course of cardiovascular pathologies, complicating the management of toxic effects associated with polychemotherapy on both the cardiac muscle and vascular system. This paper analyzes modern ideas about pathogenetic relationship between cardiovascular diseases and gastric and colon cancer. The profile and mechanism of cardiovascular toxicity of chemotherapy in patients with gastric and colon cancer, pathogenetic relationship of thyroid status and cardiovascular diseases are presented. Organizational management issues of chemotherapy toxicity are briefly highlighted.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":" 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141680532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信